Get the Stockscreener App
0.00
100.00%
-0.03
After Hours:
.03
0.03
+
Iterum Therapeutics Plc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.03
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.60M
Revenue:
-
Net Income/Loss:
$-26.96M
P/E Ratio:
0.00
EPS:
-0.7492
Net Cash Flow:
$-19.63M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.831
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.00 | 1.60M | 0 | -26.96M | -19.63M | -0.7492 |
VRTX
Vertex Pharmaceuticals Inc
|
547.29 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
814.79 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,047.10 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
149.66 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
215.44 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Iterum Therapeutics plc Revenue Breakdown – OTC:ITRMF - TradingView
Price to earnings forward of Iterum Therapeutics plc – OTC:ITRMF - TradingView
Iterum Therapeutics (ITRM) Q2 2025 earnings summary - Quartr
Iterum Therapeutics plc Actuals & Estimates (OTC:ITRMF) - TradingView
ITRMF Forecast — Price Target — Prediction for 2027 - TradingView
Iterum Therapeutics PLC (ITRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ITRMF Stock Price, News & Analysis - Stock Titan
ITRMF SEC FilingsIterum Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Iterum Therapeutics (ITRMF) files Form 25 to remove Ordinary Shares from Nasdaq - Stock Titan
Iterum Therapeutics (ITRM) Proxy Filing Summary - Quartr
Iterum Therapeutics PLC (ITRM) Institutional Confidence - TradingKey
Iterum Therapeutics PLC (ITRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Iterum Therapeutics PLC (ITRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Iterum Therapeutics PLC (ITRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Iterum Therapeutics PLC (ITRM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Iterum Therapeutics PLC (ITRM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Iterum Therapeutics (ITRM) Holds at $0.03 as Micro-Cap Biotech Waits for CatalystsNew Listing Stocks - The Legal Advocate
Iterum Therapeutics (ITRM) Holds at $0.03 as Trading Volume Remains SubduedLow Risk Entry Stocks - dars.gov.et
Iterum (ITRM) Stalls at $$0.03 — Consolidation Phase 2026-05-15Social Sentiment - The Legal Advocate
Iterum Therapeutics PLC (ITRMF) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Iterum Therapeutics PLC (ITRMF) DCF Valuation - GuruFocus
Iterum Therapeutics PLC (ITRMF) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Stock Earnings Transcripts - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Competitors 2026 - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Dividend - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Stock Price & 30 Year Financial Data - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Valuation - GuruFocus
Iterum Therapeutics PLC Stock Operating Data - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Who's Buying or Selling Iterum Therapeutics PLC (OTCM:ITRMF) Stock Today? - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) Stock News, Headlines & Updates - GuruFocus
Iterum Therapeutics PLC (OTCM:ITRMF) SEC filings - GuruFocus
ITERUM THERAPEUTICS PLC (ITRM) SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Iterum Therapeutics plc - TMX Newsfile
Iterum Therapeutics PLC (ITRMF) - MSN
Iterum Therapeutics plc Financial Disclosures & SEC Filings - TradingView
Iterum Therapeutics (ITRM) Q3 2024 earnings summary - Quartr
Iterum Therapeutics (ITRM) Investor Presentation Summary - Quartr
Iterum Therapeutics (ITRM) FDA Announcement Summary - Quartr
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
Iterum Therapeutics PLC (ITRMF) SEC filings - GuruFocus
ITRMF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Iterum Therapeutics plc (ITRMF) Competitors - Meyka
Why Is Iterum Therapeutics plc (ITRMF) Stock Down Today? - Meyka
Why Is Iterum Therapeutics plc (ITRMF) Stock Up Today? - Meyka
Iterum (ITRM) Stock Collar Strategy (Trend Strengthens) 2026-04-18Risk Analysis - Xã Thanh Hà
A 25-year pharma finance veteran takes over as Eton CFO on June 1 - Stock Titan
What's going on with Iterum Therapeutics stock Monday? - MSN
Retail Surge: Does Iterum Therapeutics plc outperform in volatile markets2026 Momentum & Comprehensive Market Scan Reports - baoquankhu1.vn
Dividend HistoryIterum Therapeutics (ITRMF) - Zacks Investment Research
Published on: 2026-04-10 21:42:25 - baoquankhu1.vn
Breakout Zone: What are the future prospects of Iterum Therapeutics plc2026 Macro Impact & Weekly Market Pulse Updates - baoquankhu1.vn
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):